PCSK-9 binding mAb (Suzhou Transcenta Therapeutics)

N/A

Report date: 2025/06/11 10:57:18

Base Information

Drug NamePCSK-9 binding mAb (Suzhou Transcenta Therapeutics)
Drug Alias NameB-9287B-9288
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody
Mechanisms of ActionProprotein convertase subtilisin kexin type 9 inhibitors
TargetsProprotein convertase subtilisin kexin type 9
Therapy Area/IndicationsHypercholesterolemia
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesSuzhou Transcenta Therapeutics Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesSuzhou Transcenta Therapeutics Co Ltd
Inactive CompaniesN/A
Active IndicationsHypercholesterolemia
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A